Respiri: Receives FDA tick for Wheezo

March 21, 2021

687

Must read

Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance for its wheezing aid, Wheezo
Wheezo monitors wheezing to manage and improve asthma
The technology can also share data with caregivers, physicians and other health care professionals
With the green tick from the FDA, the company can now market and sell the technology in the United States
Asthma is a significant problem in the U.S., with around 8 per cent of the population and 7.5 per cent of children living with the disease
On the market this afternoon, Respiri is in the grey and trading at 17 cents per share